2001
Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism
Scahill L, McCracken J, McDougle C, Aman M, Arnold L, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey D, Swiezy N, Volkmar F, Ritz L, Vitiello B. Methodological Issues in Designing a Multisite Trial of Risperidone in Children and Adolescents with Autism. Journal Of Child And Adolescent Psychopharmacology 2001, 11: 377-388. PMID: 11838820, DOI: 10.1089/104454601317261555.Peer-Reviewed Original ResearchConceptsPlacebo-controlled studyPlacebo-controlled discontinuation studyAutistic disorderSafety of risperidoneStudy of RisperidoneStandard pharmacological treatmentSelf-injurious behaviorDiscontinuation studyPharmacological treatmentClinical trialsInclusion criteriaLong-term effectsSevere tantrumsTrial designClinical relevanceClinical practiceLength of trialRisperidoneMultisite trialStudy designContinuous treatmentTrialsTreatment effectsDisordersMaintenance phase
1996
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L. A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder. JAMA Psychiatry 1996, 53: 1001-1008. PMID: 8911223, DOI: 10.1001/archpsyc.1996.01830110037005.Peer-Reviewed Original ResearchConceptsStudy of FluvoxamineAutistic disorderSelective serotonin uptake inhibitorAdverse cardiovascular eventsPlacebo-controlled trialWeeks of treatmentSerotonin uptake inhibitorSerotonin neurotransmitter systemShort-term treatmentCardiovascular eventsPlacebo groupMild sedationNeurotransmitter systemsTreatment responseSafe drugUptake inhibitorFluvoxamineSymptoms of autismFluvoxamine maleateDisordersPlaceboAutistic behaviorPatientsAdultsSymptoms